bioAffinity Technologies Files 8-K

Ticker: BIAFW · Form: 8-K · Filed: Dec 22, 2025 · CIK: 1712762

Sentiment: neutral

Topics: 8-K, filing, research

Related Tickers: BIAF

TL;DR

BIAF filed an 8-K on 12/22/25 for 'Other Events'.

AI Summary

On December 22, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates that the company is involved in commercial physical and biological research, specifically within the SIC code 8731. The report was filed as of December 22, 2025, and pertains to 'Other Events'.

Why It Matters

This 8-K filing signals an event or update from bioAffinity Technologies, Inc. that the company deems significant enough to report to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K current report for 'Other Events' and does not contain specific financial disclosures or material changes that would immediately indicate high risk.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are detailed in this 8-K filing?

The provided text is a header and does not detail the specific 'Other Events' reported in the 8-K filing.

What is the primary business of bioAffinity Technologies, Inc. according to the filing?

According to the filing, bioAffinity Technologies, Inc. is involved in 'SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH' under SIC code 8731.

When was this 8-K report filed?

The report was filed as of December 22, 2025, and the date of the earliest event reported is also December 22, 2025.

Where are bioAffinity Technologies, Inc.'s principal executive offices located?

The principal executive offices are located at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.

What is the company's state of incorporation?

The company's state of incorporation is Delaware.

Filing Stats: 1,024 words · 4 min read · ~3 pages · Grade level 12.7 · Accepted 2025-12-22 17:09:31

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 22, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing